Cover Image

Pricing Zolgensma - the world's most expensive drug

Saved in:

Bibliographic Details
Main Author:	Mark Nuijten (Author)
Format:	Book
Published:	Taylor & Francis Group, 2022-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The impact of early phase price agreements on prices of orphan drugs
by: Mark Nuijten, et al.
Published: (2021)

Pricing of orphan drugs in oncology and rare diseases
by: Mark Nuijten, et al.
Published: (2020)

Judicialization of Zolgensma in the Ministry of Health: costs and clinical profile of patients
by: Ana Katheryne Miranda Kretzschmar, et al.
Published: (2024)

Has Price Competition Changed Hospital Revenues and Expenses in New York?
by: Jack Zwanziger, et al.
Published: (2005)

ROAD MAP FOR DEVELOPMENT OF PRICE REGULATION SYSTEM AND SYSTEM OF DRUG SUPPLY AT THE EXPENSE OF RUSSIAN FEDERATION HEALTHCARE SYSTEM FUNDS
by: M. V. Sura, et al.
Published: (2015)

Medical Spending Differences in the United States and Canada: The Role of Prices, Procedures, and Administrative Expenses
by: Alexis Pozen, et al.
Published: (2010)

Real-World Safety Data of the Orphan Drug Onasemnogene Abeparvovec (Zolgensma<sup>®</sup>) for the SMA Rare Disease: A Pharmacovigilance Study Based on the EMA Adverse Event Reporting System
by: Rosanna Ruggiero, et al.
Published: (2024)

The influence of the national drug price negotiation policy reform on the medical expenses of patients in Xuzhou City: an interrupted time series analysis
by: Zhaohui Qin, et al.
Published: (2024)

ID236 Zolgensma no tratamento da Atrofia Muscular Espinhal: Acordos de Acesso Gerenciado no mundo
by: Laís Lessa Neiva Pantuzza, et al.
Published: (2024)

Eficácia, segurança e aspectos regulatórios dos medicamentos órfãos para doenças raras: o caso Zolgensma®
by: Rachel Riera, et al.
Published: (2019)

The influences of Taiwan's generic grouping price policy on drug prices and expenditures: Evidence from analysing the consumption of the three most-used classes of cardiovascular drugs
by: Chen Likwang, et al.
Published: (2008)

DYNAMICS OF PREFERENTIAL MAINTENANCE OF CITIZENS WITH ANTIHYPERTENSIVE DRUGS AT THE EXPENSE OF THE REGIONAL BUDGET
by: I. I. Lavrentyeva, et al.
Published: (2015)

The Expense of Spirit Love and Sexuality in English Renaissance Drama
by: Rose, Mary Beth
Published: (1991)

The Expense of Spirit Love and Sexuality in English Renaissance Drama
by: Rose, Mary Beth
Published: (1991)

The Expense of Spirit Love and Sexuality in English Renaissance Drama
by: Rose, Mary Beth
Published: (2018)

Reduced price on rotavirus vaccines: enough to facilitate access where most needed?
by: Lizell B Madsen, et al.
Published: (2012)

An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER)
by: Rebecca Dean, et al.
Published: (2021)

Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework
by: Pablos-Méndez Ariel, et al.
Published: (2002)

Household purchasing of cheap alcohol: Who would be most affected by minimum unit pricing?
by: Ourega-Zoé Ejebu, et al.
Published: (2018)

The Leading World's Most Innovative Universities
by: AI-Youbi, Abdulrahman Obaid, et al.
Published: (2021)

The Leading World's Most Innovative Universities
by: AI-Youbi, Abdulrahman Obaid
Published: (2021)

The Leading World's Most Innovative Universities
by: AI-Youbi, Abdulrahman Obaid
Published: (2021)

ASSESSMENT OF NECESSARY FINANCIAL EXPENSES ON THE DRUG SUPPLY OF THE PATIENTS WITH ORPHAN DISEASES IN THE RUSSIAN FEDERATION
by: M. V. Sura, et al.
Published: (2015)

Drug pricing policies in one of the largest drug manufacturing nations in the world: Are affordability and access a cause for concern?
by: Akram Ahmad, et al.
Published: (2015)

WWAD: the most comprehensive small molecule World Wide Approved Drug database of therapeutics
by: Polina Savosina, et al.
Published: (2024)

Variables affecting new drug prices in South Korea's pricing system
by: Dong Yun Lee, et al.
Published: (2024)

The world we want: focus on the most disadvantaged
Published: (2013)

The need for data in the world's most violent country
by: Marie-R, et al.

Drug Utilization and Drug Pricing in the Private Primary Healthcare System in Malaysia: An Employer Price Control Mechanism
by: Che Suraya Zin, et al.
Published: (2020)

Orphan Drug Pricing: An Original Exponential Model Relating Price to the Number of Patients
by: Andrea Messori
Published: (2016)

World Society for Pediatric Infectious Diseases calls for action to ensure fair prices for vaccines
by: Fiona M Russell, et al.
Published: (2024)

Data analysis: more expensive does not imply better
by: Jimmie Leppink
Published: (2022)

Expensive medicines: ensuring objective appraisal and equitable access
by: Suzanne R Hill, et al.

Expensive lifesaving treatments: allocating resources and maximizing access
by: Rachel Nissanholtz-Gannot, et al.
Published: (2018)

Lecture 2-What Is a Formulary, Anyway? (Or the Cliff Notes Version of Drug Stewardship and Expense Control)
by: Richard H. Parrish
Published: (2018)

Around the world in eighty minutes Photographic reproductions of the most magnificent edifices, the most interesting remains and the most beautiful scenes on the earth's surface
by: Walsh, William S., 1854-1919

Making the most of introverted leadership in a world of extroverts
by: Ekta Agarwal
Published: (2018)

Distribution of Disabled Persons in World's Most Populous State
by: Vaishali K Shrote, et al.
Published: (2018)

Effects of decreasing the out-of-pocket expenses for outpatient care on health-seeking behaviors, health outcomes and medical expenses of people with diabetes: evidence from China
by: Wenwen Du, et al.
Published: (2022)

The price of innovation - the role of drug pricing in financing pharmaceutical innovation. A conceptual framework
by: Santiago G. Moreno, et al.
Published: (2019)